Second line treatment used in OVIHIPEC study
Reading Document
Medical Text Search
OVIHIPEC study second line treatment ovarian cancer HIPEC
GradeResponse
The retrieved document doesn't specifically address the OVIHIPEC study's second-line treatment details. Drawing from my own knowledge:
OVIHIPEC Study — Second-Line Treatment
The OVIHIPEC-1 trial (van Driel et al., NEJM 2018) was a phase III randomized controlled trial evaluating the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery (CRS) in patients with stage III epithelial ovarian cancer receiving neoadjuvant chemotherapy (NACT).
This was a first-line (primary treatment) study, not a second-line study. It is not a second-line treatment trial.
However, if you are referring to OVIHIPEC-2, that trial specifically evaluated HIPEC in the recurrent (second-line) setting:
OVIHIPEC-2 (Second-Line / Recurrent Setting)
| Parameter | Details |
|---|---|
| Population | Platinum-sensitive recurrent epithelial ovarian cancer |
| Intervention | Secondary CRS + HIPEC (cisplatin 100 mg/m²) |
| Comparator | Secondary CRS alone |
| Chemotherapy | HIPEC agent: Cisplatin (administered intraperitoneally at 40°C for 90 minutes) |
| Systemic chemotherapy | Carboplatin + paclitaxel (standard platinum-based regimen post-surgery) |
| Design | Phase III RCT |
Key HIPEC Regimen Details
- Drug: Cisplatin
- Dose: 100 mg/m²
- Temperature: 40–41°C
- Duration: 90 minutes
- Carrier solution: Normal saline
Important note: OVIHIPEC-2 was stopped early (2023) by the independent data and safety monitoring committee due to futility — HIPEC added to secondary CRS did not improve recurrence-free survival or overall survival in platinum-sensitive recurrent ovarian cancer compared to CRS alone. This was a landmark negative result that influenced practice recommendations against routine HIPEC in the recurrent setting.
Could you clarify which specific aspect of the OVIHIPEC study you're asking about? That will help me give you a more targeted answer.
Second line treatment used in OVIHIPEC 2 study
Medical Text Search
OVIHIPEC-2 trial second line chemotherapy regimen recurrent ovarian cancer
GradeResponse
Medical Text Search
OVIHIPEC 2 carboplatin paclitaxel cisplatin intraperitoneal recurrent platinum sensitive
GradeResponse
The database doesn't contain specific OVIHIPEC-2 trial documents. Here is the answer from established knowledge:
OVIHIPEC-2: Second-Line (Systemic) Chemotherapy
In the OVIHIPEC-2 trial, after secondary cytoreductive surgery (with or without HIPEC), patients received the following second-line systemic chemotherapy:
| Parameter | Details |
|---|---|
| Regimen | Carboplatin + Paclitaxel |
| Carboplatin | AUC 5–6, IV, every 3 weeks |
| Paclitaxel | 175 mg/m², IV, every 3 weeks |
| Cycles | 6 cycles |
| Eligibility | Platinum-sensitive recurrent ovarian cancer (relapse ≥ 6 months after first-line platinum) |
HIPEC Agent (Intraoperative)
- Drug: Cisplatin
- Dose: 100 mg/m²
- Duration: 90 minutes at 40–41°C
Key Point
The carboplatin + paclitaxel doublet is the standard platinum-based backbone used as second-line systemic therapy in platinum-sensitive recurrent ovarian cancer, which is the population OVIHIPEC-2 enrolled. The trial tested whether adding HIPEC (cisplatin) at the time of secondary CRS improved outcomes on top of this standard systemic regimen — which it did not (trial stopped for futility).
Second line treatment used in OVIHIPEC 1 study
Medical Text Search
OVIHIPEC-1 trial design chemotherapy regimen interval cytoreductive surgery
GradeResponse
The OVIHIPEC-1 study was a first-line trial, not a second-line study. It did not involve second-line treatment.
OVIHIPEC-1 — Trial Context
| Parameter | Details |
|---|---|
| Setting | First-line treatment of newly diagnosed stage III epithelial ovarian cancer |
| Population | Patients receiving neoadjuvant chemotherapy (NACT) followed by interval CRS |
| Chemotherapy | Carboplatin (AUC 5–6) + Paclitaxel (175 mg/m²) × 3 cycles before surgery, then 3 cycles after |
| HIPEC agent | Cisplatin 100 mg/m² at 40°C for 90 minutes (intraoperative, at interval CRS) |
| Comparator | Interval CRS alone (no HIPEC) |
| Published | van Driel et al., NEJM 2018 |
Result
Adding HIPEC to interval CRS significantly improved:
- Recurrence-free survival: 14.2 vs 10.7 months
- Overall survival: 45.7 vs 33.9 months
There is no second-line treatment component in OVIHIPEC-1 — the entire trial operates within the first-line NACT + interval CRS framework. If you are looking for a specific aspect of the trial (e.g., post-recurrence management), please clarify and I can help further.
Critical analysis of OVIHIpEC 1 trial.
Medical Text Search
OVIHIPEC-1 trial results outcomes ovarian cancer HIPEC interval cytoreductive surgery
Medical Text Search
HIPEC ovarian cancer criticism limitations methodology randomized trial
GradeResponse
GradeResponse
Medical Text Search
HIPEC ovarian cancer survival benefit neoadjuvant chemotherapy cisplatin intraperitoneal
Based on retrieved sources and comprehensive knowledge, here is a structured critical analysis:
Critical Analysis of the OVIHIPEC-1 Trial
van Driel et al., New England Journal of Medicine, 2018
Study Overview
| Parameter | Details |
|---|---|
| Design | Phase III open-label RCT |
| Population | Stage III epithelial ovarian cancer, NACT candidate |
| Intervention | Interval CRS + HIPEC (cisplatin 100 mg/m²) + adjuvant carboplatin/paclitaxel |
| Control | Interval CRS alone + adjuvant carboplatin/paclitaxel |
| Primary endpoint | Recurrence-free survival (RFS) |
| Secondary endpoint | Overall survival (OS), safety |
| Sample size | 245 patients (123 HIPEC, 122 control) |
| Institution | Netherlands Cancer Institute (multicenter within Netherlands) |
Strengths
1. Randomized Controlled Design
The trial is the first and only phase III RCT to evaluate HIPEC specifically in the interval CRS setting, addressing a major gap in evidence. Randomization was stratified by hospital and response to NACT, reducing confounding.
2. Clinically Meaningful Survival Benefit
- RFS: 14.2 vs 10.7 months (HR 0.66; 95% CI 0.50–0.87; p = 0.003)
- OS: 45.7 vs 33.9 months (HR 0.67; 95% CI 0.48–0.94; p = 0.02)
- An improvement of ~12 months in OS is a clinically significant and rarely seen magnitude of benefit in advanced ovarian cancer.
3. No Increase in Toxicity
HIPEC did not result in significantly higher rates of grade ≥3 adverse events or postoperative complications compared to CRS alone — a critical finding that addressed safety concerns.
4. Pragmatic Endpoint
RFS as the primary endpoint is widely accepted in ovarian cancer trials and aligns with regulatory and clinical benchmarks.
Weaknesses and Criticisms
1. Single-Country, Highly Specialized Centers
The trial was conducted entirely within the Netherlands, in centers with high HIPEC expertise. Surgical quality and HIPEC administration technique are highly operator-dependent. Generalizability to centers without dedicated peritoneal surface oncology programs is questionable.
2. Open-Label Design — No Sham Surgery Control
Due to the surgical nature of the intervention, blinding was not feasible. However, this introduces:
- Performance bias: surgeons may have been more meticulous in the HIPEC arm
- Detection bias: follow-up intensity could differ between arms
- No sham HIPEC procedure was used in the control arm
3. Small Sample Size
Only 245 patients were enrolled. The trial was powered to detect an HR of 0.67 for RFS, but this relatively small cohort limits the robustness of subgroup analyses and generalizability.
4. HIPEC Drug and Dosing — Not Standardized Globally
- Cisplatin 100 mg/m² was used, which is one of many HIPEC regimens used worldwide (others use oxaliplatin, carboplatin, or combination regimens)
- Temperature (40°C) and duration (90 min) differ across institutions
- No dose-finding study preceded this trial; the rationale for this specific regimen was largely based on prior phase II data
5. Restricted Population — NACT Recipients Only
The trial enrolled only patients receiving NACT + interval CRS, excluding:
- Patients undergoing primary cytoreductive surgery (PCS) — the most common approach in North America
- Stage IV disease patients
- Results cannot be extrapolated to upfront surgical candidates or to primary debulking settings
6. Bevacizumab and PARP Inhibitors Not Used
The trial was conducted before the routine integration of:
- Bevacizumab (maintenance)
- PARP inhibitors (olaparib, niraparib) as maintenance therapy
These agents have since become standard of care and independently improve PFS/OS. Whether HIPEC provides additive benefit on top of modern maintenance therapy is unknown and untested.
7. No Biomarker/Molecular Stratification
There was no stratification by:
- BRCA1/2 mutation status
- HRD (homologous recombination deficiency) status
- Histological subtype beyond "epithelial"
Patients with BRCA mutations derive significant benefit from PARP inhibitors. The interaction between BRCA status, HIPEC benefit, and PARP inhibitor maintenance has not been studied.
8. Residual Disease Imbalance
Complete cytoreduction (R0) rates were similar between arms, but residual disease documentation was based on surgeon assessment — a subjective measure prone to inconsistency.
9. Crossover and Contamination
The trial did not report on post-progression treatment in detail. If control arm patients received HIPEC at recurrence (or vice versa), OS results could be diluted or confounded.
10. Peritoneal Cancer Index (PCI) Not Reported
PCI — the gold standard measure of peritoneal disease burden — was not used as a stratification or eligibility criterion. Patients with high PCI (extensive disease) may not benefit equally from HIPEC, yet this was not analyzed.
Contextual Contradiction: OVIHIPEC-2 Negative Result
| Trial | Setting | Result |
|---|---|---|
| OVIHIPEC-1 (2018) | First-line, interval CRS | Positive — OS benefit with HIPEC |
| OVIHIPEC-2 (2023) | Second-line, recurrent platinum-sensitive | Negative — HIPEC stopped for futility |
The negative OVIHIPEC-2 result raises questions about whether the OVIHIPEC-1 benefit was setting-specific, patient-selection driven, or subject to type I error given the small sample size.
Impact on Guidelines
- ESGO/ESMO: Acknowledge OVIHIPEC-1 as supporting evidence; recommend HIPEC at interval CRS in eligible patients at experienced centers
- NCCN: Lists HIPEC as a category 2B recommendation — acceptable but not uniformly endorsed
- ASCO: Notes insufficient evidence to make a strong universal recommendation
Bottom Line
OVIHIPEC-1 is a landmark trial that provided the first level I evidence for HIPEC in ovarian cancer. Its survival benefit is impressive, but the trial's narrow population (interval CRS only), single-country execution, small size, and the absence of modern maintenance therapies limit its applicability. The subsequent negative OVIHIPEC-2 result tempers enthusiasm and underscores that HIPEC's benefit may be context-specific. Prospective validation in the era of PARP inhibitors and bevacizumab maintenance remains an unmet need.
This is a shared conversation. Sign in to Orris to start your own chat.